MOTION
Vimseltinib shrank tenosynovial giant cell tumours in 40% of patients versus none on placebo, with better joint function.
ORR 40% vs 0% at week 25; improvements in active range of motion, pain, stiffness and function (Lancet 2024). Approved February 2025.
Setting
Symptomatic tenosynovial giant cell tumour not amenable to surgery: vimseltinib vs placebo
Phase
Phase 3
Sponsor
Deciphera
Registry
Headline result
ORR 40% vs 0%.
Reported
2024
Enrolled
123
In plain words
What these results mean for people, not percentages
Objective response rate at week 25primaryresponse endpoint
- 40 vs 0 out of 100 had their tumour shrink with Vimseltinib compared with Placebo; 40 more per 100.
- Roughly one extra person helped for every 3 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- The p-value (<0.0001) says a difference this large would rarely happen by chance; it does not say how large or how useful the difference is.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Symptomatic tenosynovial giant cell tumour not amenable to surgery: vimseltinib vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.